These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 29138327)

  • 1. Highly Efficacious Novel Vaccine, Humoral Immunity, and Ocular Herpes Simplex Virus 1: Reality or Myth?
    Ghiasi H
    J Virol; 2017 Dec; 91(23):. PubMed ID: 29138327
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to "Highly Efficacious Novel Vaccine, Humoral Immunity, and Ocular Herpes Simplex Virus 1: Reality or Myth?".
    Royer DJ; Carr DJJ
    J Virol; 2017 Dec; 91(23):. PubMed ID: 29138328
    [No Abstract]   [Full Text] [Related]  

  • 3. Modelling efforts needed to advance herpes simplex virus (HSV) vaccine development: Key findings from the World Health Organization Consultation on HSV Vaccine Impact Modelling.
    Gottlieb SL; Giersing B; Boily MC; Chesson H; Looker KJ; Schiffer J; Spicknall I; Hutubessy R; Broutet N;
    Vaccine; 2019 Nov; 37(50):7336-7345. PubMed ID: 28647165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meeting report: Initial World Health Organization consultation on herpes simplex virus (HSV) vaccine preferred product characteristics, March 2017.
    Gottlieb SL; Giersing BK; Hickling J; Jones R; Deal C; Kaslow DC;
    Vaccine; 2019 Nov; 37(50):7408-7418. PubMed ID: 29224963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between herpes simplex virus neutralizing antibody titers determined by ELVIS cell and traditional plaque reduction assays.
    Blevins TP; Yu Y; Belshe RB; Bellamy AR; Morrison LA
    PLoS One; 2019; 14(4):e0214467. PubMed ID: 30946751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T cell immunity to herpes simplex viruses in seronegative subjects: silent infection or acquired immunity?
    Posavad CM; Wald A; Hosken N; Huang ML; Koelle DM; Ashley RL; Corey L
    J Immunol; 2003 Apr; 170(8):4380-8. PubMed ID: 12682275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccines for Herpes Simplex: Recent Progress Driven by Viral and Adjuvant Immunology.
    Sandgren KJ; Truong NR; Smith JB; Bertram K; Cunningham AL
    Methods Mol Biol; 2020; 2060():31-56. PubMed ID: 31617171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New concepts in herpes simplex virus vaccine development: notes from the battlefield.
    Dasgupta G; Chentoufi AA; Nesburn AB; Wechsler SL; BenMohamed L
    Expert Rev Vaccines; 2009 Aug; 8(8):1023-35. PubMed ID: 19627185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccine value profile for herpes simplex virus.
    Johnston C; Scheele S; Bachmann L; Boily MC; Chaiyakunapruk N; Deal C; Delany-Moretlwe S; Lee S; Looker K; Marshall C; Mello MB; Ndowa F; Gottlieb S
    Vaccine; 2024 Jul; 42(19S1):S82-S100. PubMed ID: 39003018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Highly Efficacious Herpes Simplex Virus 1 Vaccine Blocks Viral Pathogenesis and Prevents Corneal Immunopathology via Humoral Immunity.
    Royer DJ; Gurung HR; Jinkins JK; Geltz JJ; Wu JL; Halford WP; Carr DJJ
    J Virol; 2016 Jun; 90(11):5514-5529. PubMed ID: 27030264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seroprevalence of HSV-1 and HSV-2 antibodies in Canadian women screened for enrolment in a herpes simplex virus vaccine trial.
    Gorfinkel IS; Aoki F; McNeil S; Dionne M; Shafran SD; Zickler P; Halperin S; Langley J; Bellamy A; Schulte J; Heineman T; Belshe R
    Int J STD AIDS; 2013 May; 24(5):345-9. PubMed ID: 23970700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential prophylactic and therapeutic vaccines for HSV infections.
    Ramachandran S; Kinchington PR
    Curr Pharm Des; 2007; 13(19):1965-73. PubMed ID: 17627530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Towards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknown.
    Chentoufi AA; Kritzer E; Yu DM; Nesburn AB; Benmohamed L
    Clin Dev Immunol; 2012; 2012():187585. PubMed ID: 22548113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response.
    Bettahi I; Zhang X; Afifi RE; BenMohamed L
    Viral Immunol; 2006; 19(2):220-36. PubMed ID: 16817765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genital herpes vaccines--cause for cautious optimism.
    Haddow LJ; Mindel A
    Sex Health; 2006 Mar; 3(1):1-4. PubMed ID: 16607967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations of HLA-A, HLA-B and HLA-C alleles frequency with prevalence of herpes simplex virus infections and diseases across global populations: implication for the development of an universal CD8+ T-cell epitope-based vaccine.
    Samandary S; Kridane-Miledi H; Sandoval JS; Choudhury Z; Langa-Vives F; Spencer D; Chentoufi AA; Lemonnier FA; BenMohamed L
    Hum Immunol; 2014 Aug; 75(8):715-29. PubMed ID: 24798939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A lentiviral vector-based, herpes simplex virus 1 (HSV-1) glycoprotein B vaccine affords cross-protection against HSV-1 and HSV-2 genital infections.
    Chiuppesi F; Vannucci L; De Luca A; Lai M; Matteoli B; Freer G; Manservigi R; Ceccherini-Nelli L; Maggi F; Bendinelli M; Pistello M
    J Virol; 2012 Jun; 86(12):6563-74. PubMed ID: 22491465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Vaccines as an approach to the immunocorrection in herpetic infections].
    Barinskiĭ IF; Alimbarova LM; Lazarenko AA; Makhmudov FR; Sergeev OV
    Vopr Virusol; 2014; 59(1):5-11. PubMed ID: 25065139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicentre clinical trial with herpes simplex virus vaccine in recurrent herpes infection.
    Mastrolorenzo A; Tiradritti L; Salimbeni L; Zuccati G
    Int J STD AIDS; 1995; 6(6):431-5. PubMed ID: 8845402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.